In mantle cell lymphoma (MCL), resistance to ibrutinib (the BCR antagonist that targets Bruton’s tyrosine kinase) is characterised by aberrant non-canonical NF-kB signalling due to mutations in TRAF2 and BIRC3 [11]. The gene discussed is TRAF2; the disease is mantle cell lymphoma.